VYGR Similar Chart Price Prediction
The price of VYGR is predicted to go up -18.85%, based on the high correlation periods with TLSI. The similarity of these two price pattern on the periods is 97.73%.
VYGR
TLSI
Down: -18.85%Similarity: 97.73%
VYGR Revenue Forecast
VYGR EPS Forecast
VYGR FAQs
What is bull’s view on VYGR?
What is bear's view on VYGR?
What is VYGR revenue forecast for next quarter？
VYGR Analyst's Forecast
Samantha Semenkow
Citigroup
Strong Buy
2024-12-02
Price Target
$12
Upside
+73.16%
Citi initiated coverage of Voyager Therapeutics with a Buy rating and $12 price target. Voyager is an early clinical-staged biotech developing therapies for the treatment of neurological disorders, the analyst tells investors in a research note. The firm sees "meaningful value" in Voyager's platform from both a clinical and business development perspective. The company's anti-tau antibody, VY7523, is currently in a Phase 1a for healthy volunteers with data expected in the first half of 2025, Citi points out.
Lili Nsongo
Leerink Partners
Buy
2024-10-16
Price Target
$15
Upside
+89.63%
